Altus Pushes Back Phase III Timeline On Lead Products
This article was originally published in The Pink Sheet Daily
Inconsistencies in a test lot of Altus’ oral pancreatic enzyme insufficiency product deferred one trial; failure of a supplier to deliver critical equipment postponed a trial for its human growth hormone product.
You may also be interested in...
The growth hormone candidate offers once-weekly dosing for adults and children.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.